Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia
NCT06429449Phase 1Recruiting
- Sponsor
- University of Colorado Denver
- Start
- Jul 2024
- Primary completion
- Dec 2026
- Modality
- Lipid-based Nanoparticles, CAR-T Cells, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells in acute myeloid leukemia (AML) (4 cohorts), sponsored by University of Colorado Denver. Primary endpoints: Maximum Tolerated Dose, Overall Response Rate up to 1 year and 1 more. Started Jul 2024; status: recruiting.
02
Drugs
mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06429449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06429449.